News
Lenacapavir, marketed under the brand name Yeztugo, has been shown to reduce the risk of HIV transmission by more than 99.9% ...
Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo from company Gilead Sciences, remained ...
A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
(MENAFN- PR Newswire) HIV/AIDS remains a critical global health challenge today ... Current antiretroviral therapy (" ART ") ...
"This really has the possibility of ending HIV transmission," said Greg Millett, public policy director at The Foundation for ...
The Genesee County Health Department is offering no-cost testing during National HIV Testing Day at the Genesee Free Medical ...
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV – a move the company hailed as a major breakthrough in the fight against the sexually ...
3h
Atlanta News First on MSNFDA approves ‘life-saving’ HIV prevention shotThe FDA approved the first and only twice a year HIV prevention shot, called Lenacapvir. It was created by leading antiviral drug maker, Gilead. Lenacapvir is being hailed as the “next best thing” in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results